Geron Corp (GERN) Dividend History

Company News

• GERN Investors are Reminded of an Opportunity to Lead Geron Corporation Securities Fraud Lawsuit with the Schall Law Firm

  Geron Corporation (GERN) is facing a securities fraud lawsuit for allegedly making false and misleading statements about its drug Rytelo's launch and potential growth, leading to investor losses.

  Benzinga
• Faruqi & Faruqi Reminds Geron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 12, 2025 - GERN

  Faruqi & Faruqi, LLP is investigating potential claims against Geron Corporation (GERN) for making false and/or misleading statements about its drug Rytelo. The company's stock price declined significantly after it announced that Rytelo's growth had flattened due to seasonality, competition, lack of awareness, and the burden of the monitoring requirement.

  GlobeNewswire Inc.
• INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 3D Systems Corporation - DDD

  3D Systems Corporation reported weak financial results for Q4 2024, missing consensus estimates for sales, operating income, and earnings. This led to a 20.96% drop in the company's stock price.

  GlobeNewswire Inc.

  Featured Companies: DDD HUM
• INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Geron Corporation and Certain Officers – GERN

  Geron Corporation, a biopharmaceutical company, is facing a class action lawsuit over alleged violations of federal securities laws related to the launch and commercialization of its drug RYTELO for the treatment of lower-risk myelodysplastic syndromes.

  GlobeNewswire Inc.
• Why Geron Stock Crept Higher Today

  Geron, a commercial-stage biotech company, reported its Q1 2023 results, which fell short of analyst expectations. While the company's cancer drug Rytelo generated $39.6 million in sales, it was lower than the $50.5 million analysts had projected. Geron maintained its guidance for operating expenses and cash runway.

  The Motley Fool